Production (Stage)
Intensity Therapeutics, Inc.
INTS
$0.4805
$0.01753.78%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 5.37M | 6.09M | 6.40M | 6.12M | 4.98M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 15.24M | 16.59M | 16.73M | 15.66M | 11.81M |
Operating Income | -15.24M | -16.59M | -16.73M | -15.66M | -11.81M |
Income Before Tax | -15.01M | -16.27M | -16.26M | -15.08M | -13.81M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -15.01 | -16.27 | -16.26 | -15.08 | -13.81 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -15.01M | -16.27M | -16.26M | -15.08M | -13.81M |
EBIT | -15.24M | -16.59M | -16.73M | -15.66M | -11.81M |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -1.06 | -1.17 | -1.18 | -1.10 | -2.17 |
Normalized Basic EPS | -0.66 | -0.73 | -0.74 | -0.69 | -0.72 |
EPS Diluted | -1.28 | -1.39 | -1.18 | -1.10 | -2.17 |
Normalized Diluted EPS | -0.66 | -0.73 | -0.74 | -0.69 | -0.72 |
Average Basic Shares Outstanding | 57.09M | 55.63M | 54.99M | 54.85M | 44.65M |
Average Diluted Shares Outstanding | 57.09M | 55.63M | 54.99M | 54.85M | 44.65M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |